Physician profile
Patrick Albertus
NPI 1730718966
$919.26
in general payments reported to CMS, 2019-2025
14 companies · $741 in 2025
The $741 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $178 · 2025: $741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $919.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $180.26 | 2024-2025 | Impella |
| Amgen INC. | $138.92 | 2024 | |
| Shockwave Medical, INC | $114.72 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $77.54 | 2025 | |
| Chiesi USA, INC. | $68.53 | 2024-2025 | Kengreal, Cleviprex |
| Pfizer INC. | $60.00 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.88 | 2025 | Jardiance |
| Abbott Laboratories | $46.98 | 2025 | Cardiomems, Aveir |
| Bayer Healthcare Pharmaceuticals INC. | $46.95 | 2025 | |
| Medtronic, INC. | $46.08 | 2025 | Cobalt Dr Mri Surescan |
| Terumo Medical Corporation | $25.65 | 2025 | Glidewire, Metacross Otw, Progreat |
| Actelion Pharmaceuticals US, INC. | $23.88 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $18.99 | 2025 | Camzyos |
| Idorsia Pharmaceuticals US INC | $15.88 | 2025 | Tryvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Albertus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.